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Posttranslational modiﬁcation of proteins with ubiquitin and ubiquitin-like modiﬁers such as SUMO can
be reverted by speciﬁc proteases, also referred to as deubiquitinases and isopeptidases, most of which are
cysteine-dependent. We have found that the replacement of the conserved C-terminal glycine with prop-
argylamine converts SUMO and ubiquitin to highly efﬁcient covalent inhibitors of their cognate cysteine
proteases. Attack of the catalytic cysteine onto the terminal alkyne results in the formation of a vinyl sul-
ﬁde linkage. Although this reaction is reminiscent of the inhibitory mechanism of the isosteric nitrile
inhibitors it was unexpected due to the low electrophilicity of the alkyne group. We show that a precise
location of the functional group in the active site of the protease is crucial for the reaction, which was not
inhibited by the presence of a radical scavenger. Furthermore, a mutational study of key catalytic residues
in the SUMO-protease Senp1, that is H533A and D550A of the catalytic triad and Q597A as part of the
oxyanion hole, revealed that these residues are not required for the observed covalent adduct formation.
We therefore propose that the reaction is an in situ thiol–alkyne addition. Due to the high chemical inert-
ness of the alkyne moiety the respective protease inhibitors should be well-suited for cellular and ther-
apeutic applications. In keeping with this idea, selective labeling with propargylated SUMO and Ub
probes was observed in lysates of cell lines expressing the cognate proteases after transient transfection.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Posttranslational modiﬁcations of proteins with ubiquitin (Ub)
and ubiquitin-like (Ubl) modiﬁers like SUMO and Nedd8 play
essential roles in many cellular processes in health and disease.1–4
These small proteins are connected via their carboxy terminus to
selected target proteins, inmost cases to the amino group of a lysine
side chain to give an isopeptide bond. The reverse reaction is
brought about by hydrolysis through speciﬁc proteases, which are
also responsible for the maturation of the initially expressed Ub
and Ubl precursors. About 100 deubiquitinases (also referred to as
DUBs or isopeptidases), of which the majority represents cys-
teine-dependent enzymes, and about half a dozen of SUMO-speciﬁc
proteases have been identiﬁed so far to be encoded by the human
genome.5–9 Some of these are more specialized in cleaving the iso-
peptide bonds, whereas others are dedicated to peptide bond
hydrolysis in the maturation step. The interplay between conjuga-
tion and deconjugation is important for the dynamics and regula-
tion of this modiﬁcation as well as for Ub and Ubl recycling prior
to degradation of the target protein. It is therefore not surprising
that DUBs and Ubl proteases are considered promising drugtargets.10 To speciﬁcally inhibit the cysteine-dependent proteases
of this group, concepts for covalent inhibitors of other therapeuti-
cally important cysteine proteases like the cathepsins and the
caspases have been exploited.11,12 To this end, various functional
groups as warheads directed against the active-site cysteine were
attached to the C-terminus of ubiquitin, SUMO, Nedd8 and other
Ubl proteins, ranging from aldehyde13 to nitrile,14 vinylsulfone,15
alkylhalide, vinylester, vinylcyanide,16 b-lactone, benzyloxymeth-
ylketone17 and ﬂuoromethylketone.18 The Ub and Ubl proteins
equipped with these electrophilic groups were also extensively
used for the identiﬁcation of newmembers of the cognate proteases
by labeling experiments in cell lysates.
Previously, we19–21 and others22 reported the site-speciﬁc
attachment of Ub and Ubl modiﬁers to recombinant target proteins
by the copper-catalyzed alkyne–azide cycloaddition (CuAAC or
click chemistry).23,24 This chemical conjugation approach serves
to circumvent limitations of the enzymatic conjugation using puri-
ﬁed proteins with regard to the difﬁculty to prepare deﬁned and
homogenous conjugates. While in our approaches the azide func-
tional group was incorporated into the target protein either via
cysteine derivatization19 or by unnatural amino acid mutagene-
sis,20,21 the terminal alkyne group was introduced into the Ub or
Ubl protein by aminolysis of an intein-generated protein thioester
with propargylamine (Pa).19–21 In order to resemble the length of
Figure 1. Propargylated SUMO2 covalently reacts with SUMO-speciﬁc proteases. (A) Schematic representation of the SUMO2 constructs used in this study in comparison to a
native isopeptide-linked SUMO2. The position of the carbonyl C-atom attacked by SUMO-proteases in the isopeptide bond is marked by a red dashed line; (B) various SUMO
probes were incubated with yeast Ulp1 for 1 h. The newly formed covalent adduct is indicated; (C) assays with human Senp1 carried out for 1 h; (D) time-dependent covalent
adduct formation of SUMO2(DG)-Pa with Senp1 in comparison to SUMO2(DG)–Ba. All reactions in (B–D) were performed at room temperature and subsequently analyzed by
denaturing and reducing SDS–PAGE (Coomassie-stained).
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native isopeptide bond, we had employed Ub and SUMO con-
structs in which either one or both of the conserved C-terminal
glycine residues were deleted (Fig. 1A). So far, alkynes have
not been reported as functional moieties to inhibit cysteine
proteases.25
Alkynes are considered bioorthogonal at physiological condi-
tions, that is inert for reactions with biological molecules.23,24
This is best reﬂected by the use of terminal alkynes for a pleth-
ora of speciﬁc cellular applications in combination with click
chemistry, including the afﬁnity-based proﬁling of cysteine pro-
teases in which the alkyne group serves to attach a ﬂuorophore
or biotin moiety following the actual suicide inhibition of the en-
zyme.26–29
2. Materials and methods
2.1. General procedures and materials
For DNA cloning and protein expression standard molecular
biology protocols were applied. Antibiotics were used at concen-
trations of 100 lg/ml (ampicillin), 50 lg/ml (kanamycin) and
34 lg/ml (chloramphenicol), respectively. Synthetic oligonucleo-
tides were purchased from Biolegio (Nijmegen, the Netherlands).
Site-directed mutagenesis was performed according to the
QuikChange protocol (Stratagene). All generated plasmids were
conﬁrmed by DNA-sequencing (GATC Biotech, Konstanz, Germany
and Seqlab, Göttingen, Germany). Propargylamine, 3-butynyl-
amine and allylamine were purchased from Sigma–Aldrich,
Munich, Germany. HA–SUMO2–Vinylsulfone, here termed SU-
MO2(DG)–VS, was ordered from BostonBiochem, Cambridge,
USA. Monoclonal anti-HA (HA.11 Clone 16B12) and anti-EGFP
antibodies were from Covance, Berkeley, USA. Polyclonal HRP-
conjugated rabbit anti-mouse antibodies were used from Dako,
Hamburg, Germany.2.2. Expression plasmids
The gene fragment encoding SUMO2(DG)–GyrA–CBD was PCR-
ampliﬁed from pSS0120 and cloned into the NcoI and HindIII sites
of pET28a (Novagen) to give pSS15 encoding HA–SUMO2(DG)–
GyrA–CBD. A triplet codon for C-terminal Gly residue of Smt3 was
introduced into pNW05 (encoding His6–Smt3(DGG)–GyrA–CBD)19
by site-directed mutagenesis to give pSS36 encoding His6–
Smt3(DG)–GyrA–CBD; Site-directed mutagenesis using pGST–Sen-
p1(aa419–644) as template (this plasmid was kindly provided by
Frauke Melchior (ZMBH Heidelberg, Germany)) was carried out to
give pSS22, pSS23, pSS24, and pSS37 encoding the C603S, H533A,
D550A, and Q597A mutants, respectively, of GST–Senp1, as well as
using pUbc920 as a template to give pSS35 encoding the C93A mu-
tant of Ubc9. Plasmids pNW13,19 pSS01,20 pSS14,20 pNW3120 and
pNW0719 encoding His6–SUMO2(DGG)–GyrA–CBD, His6–SU-
MO2(DG)–GyrA–CBD, His6–SUMO2(Q98R)(DG)–GyrA–CBD, SBP–
Ub(DG)–GyrA–CBD, and SBP–HA–GpD–PML11, respectively, were
previously published. The plasmids for bacterial expression of
His6-T7-USP5 and eukaryotic expression of HA–USP5 were kindly
provided by Frauke Melchior. The plasmid encoding His6–Ulp1
(aa403-621) was a kind gift from Kirill Alexandrov (University of
Queensland, Australia). The plasmid encoding Ub(DG)–VMA–CBD
was kindly providedbyKeithWilkinson (EmoryUniversity, Georgia,
USA). Theplasmid for EGFP-Senp230 initially createdbyMarryDasso
(NICHD, Bethesda, USA), was ordered from Addgene. Plasmids used
for in vivo SUMOylation reactions31 encoding Aos1/Uba2, Ubc9 and
His6–SUMO1were kindly provided by Gerrit Praefcke (University of
Cologne, Germany).
2.3. Protein expression, puriﬁcation, and C-terminal
modiﬁcation
For the recombinant expression of proteins, Escherichia coli
BL21(DE3) cells transformed with the respective plasmids were
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priate antibiotics at 37 C to an OD600 of 0.6 before protein expres-
sion was induced with 0.4 mM IPTG at 28 C. After 4 h, cells were
harvested by centrifugation, resuspended in a suitable buffer and
lysed by two passages through an Avestin C5 emulsiﬁer. Insoluble
cell debris was removed by centrifugation. CBD-tagged SUMO and
Ub intein constructs were immobilized on chitin beads (New Eng-
land Biolabs) equilibrated with chitin column buffer (20 mM
HEPES, 500 mM NaCl, 1 mM EDTA, pH 8.0). The beads were incu-
bated with the clariﬁed cell lysate for 1 h at 4 C before being
washed with 20 column volumes (CV) chitin column buffer. On-
column thiolysis and aminolysis were initiated by the addition of
chitin column buffer containing 250 mM 2-mercaptosulfonic acid
and the desired amine (250 mM propargylamine, 500 mM 3-buty-
nylamine or 500 mM allylamine). To obtain the proteins with the
free carboxyl terminus 250 mM DTT was added. After incubation
for 24–48 h at 4 C under slight agitation, the cleavage efﬁciency
was analyzed by SDS–PAGE. If uncleaved and unbound starting
material was still present, the solution was passed again over fresh
chitin beads. Subsequently, the solution was dialyzed against dial-
ysis buffer (20 mM HEPES, 150 mM NaCl, pH 8.0). For the puriﬁca-
tion of GST–Senp1 constructs, the clariﬁed cell lysate was applied
twice to a GST-bind resin (Novagen, Darmstadt, Germany) equili-
brated in GST-bind/wash buffer (4.3 mM Na2HPO4, 1.47 mM
KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.3). The column was
washed with 10 CV GST-bind/wash buffer prior to elution with
six times 0.5 CV GST-elution buffer (50 mM Tris, 10 mM red gluta-
thione, pH 8.0). Fractions containing the puriﬁed protein were
pooled and dialyzed against dialysis buffer supplemented with
1 mM DTT. His6-tagged proteins were puriﬁed over a Ni-NTA-aga-
rose column (Invitrogen) equilibrated in buffer A (50 mM Tris,
300 mM NaCl, pH 8.0) and supplemented with 10 mM imidazole.
The beads were washed with 10 CV buffer A (+20 mM imidazole)
and 5 CV buffer A (+40 mM imidazole). The elution was performed
by the addition of six times 0.5 CV buffer A (+250 mM imidazole).
Puriﬁed proteins were dialyzed against dialysis buffer. Proteins
fused to an SBP-Tag were bound to streptactin sepharose (IBA
GmbH, Göttingen, Germany) equilibrated with buffer W (100 mM
Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0). After washing the column
with 10 CV buffer W, the protein was eluted with six times 0.5 CV
buffer W containing 2 mM desthiobiotin followed by dialysis
against dialysis buffer. Ubc9 was puriﬁed via cation exchange chro-
matography according to the protocol previously reported.32
2.4. Covalent adduct formation
If not indicated differently, puriﬁed Ubl(DG) proteins C-termi-
nally modiﬁed with propargylamine, allylamine, 3-butynylamine,
or vinylsulfone were incubated with puriﬁed Ubl deconjugating
enzymes or Ubc9 at room temperate in a 2:1 molar ratio at concen-
trations between 2 and 10 lM. Aliquots were removed from the
reaction mixture at the indicated time points and the reaction
was stopped by the addition of SDS sample buffer and directly boil-
ing the samples. Pre-incubation of the proteases with 10 mM NEM
was carried out for 30 min at room temperature prior to the addi-
tion of the alkyne-probe.
2.5. Mass spectrometry
The protein samples were digested with Trypsin (Promega)
according to the manufacturer’s protocol. The corresponding pep-
tide mixtures were analyzed with an Agilent 1100 HPLC system
coupled to a LTQ–FT–Ultra mass analyzer (Thermo Scientiﬁc) using
a Phenomenex 150/3 Kinetex C18 column (2.6 lm particle size,
100 A pore diameter) at 60 C and a ﬂow rate of 0.2 ml/min. The
gradient applied was as follows (solvent A: 0.1% TFA/water; solventB: 0.1% TFA in MeCN): Holding 5% B for 10 min, then linear increase
of the concentration of B within 150 min to 60% B followed by an
increase to 90% B within 5 min and holding 90% B for additional
15 min. Exact mass spectra of the eluting peptides were generated
within the FT–ICR mass analyzer at a resolution of 100,000. Addi-
tionally, data dependent fragmentation was performed within
the LTQ mass analyzer. ESI-MS analysis of intact, allylamine and
3-butynylamine modiﬁed SUMO2(DG) was performed using the
LTQ orbitrap XL (Thermo Scientiﬁc). Multiply charged ESI-MS spec-
tra were deconvoluted to the uncharged mass.
2.6. Labeling in cell lysates
Mouse neuroblastoma N2a-cells were cultured in DMEM (Pan
Biotech GmbH, Aidenbach, Germany) supplemented with 10%
FCS, 1% penicillin/streptomycin, 1% L-glutamine and 1% sodium
pyruvate at 37 C under 5% CO2. The cells were transiently trans-
fected with the plasmids encoding HA–USP5 or EGFP–Senp2 using
GeneJuice transfection reagent (Novagen) according to the manu-
facturer’s protocol. 24 h after transfection, the cells were washed
with ice cold PBS (140 mM NaCl, 3 mM KCl, 8 mM Na2HPO4,
1.5 mM KH2PO4, pH 7.4) and scraped off from the culture dish.
After centrifugation, the harvested cells were incubated with
100 ll ELB buffer (50 mM Tris pH 7.5, 120 mM NaCl, 20 mM NaF,
1 mM EDTA, 6 mM EGTA, 15 mM NaPPi, 0.1% NP40) for 1 h on
ice. Cellular debris was then removed by centrifugation and the
supernatant was directly used for labeling experiments. The ly-
sates were incubated with different concentrations of modiﬁed
Ubl(DG) proteins for various periods of time at room temperature
as indicated. In some cases a pre-treatment of the lysate with
10 mM N-ethylmaleimide (NEM) for 30 min on ice prior to the
addition of the alkyne-probe was performed. The analyses of all
reactions were carried out by western blotting.3. Results and discussion
3.1. Covalent adduct formation between a propargylated SUMO
and a SUMO protease
To our surprise, we observed that alkyne-functionalized human
SUMO (SUMO2 isoform) with the last glycine residue deleted,
termed SUMO2(DG)–Pa (Fig. 1A), reacted efﬁciently with the hu-
man SUMO protease Senp1 as well as with the yeast homolog
Ulp1 to form stoichiometric adducts. The adducts were stable under
the denaturing and reducing SDS–PAGE conditions and migrated at
the molecular weights corresponding to the sum of both protein
components (Fig. 1B and C), indicating that formation of a covalent
bond had occurred. The reaction was strictly dependent on the
presence of the propargylmoiety at the position of the terminal gly-
cine, because control reactions with SUMO constructs either having
the native glycine at this position and lacking the propargyl moiety
or lacking both glycines failed to show similar adduct formation
(Fig. 1B and C). Furthermore, a construct in which the propargyl
group was replaced with an allyl moiety did not react (Fig. S1).
Time-course experiments revealed that Senp1 formed the new spe-
cies with SUMO2(DG)–Pa very rapidly with almost quantitative
conversion at the ﬁrst time-point investigated 30 sec after mixing
both components (Fig. 1D & Fig. S2A). Ulp1 reacted somewhat
slower with this heterologous SUMO isoform, but with a similar
rate with its cognate SUMO probe from yeast, Smt3(DG)–Pa
(Fig. S2B), indicating that the speciﬁc recognition between the
two proteins is important for the high rate of the reaction. In order
to further understand the nature of this unexpected reaction, we
noticed that the position of the quaternary carbon atom of the ethy-
nyl group in SUMO2(DG)–Pa corresponded to that of the carbon
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nucleophile attack by the catalytic cysteine of the protease
(Fig. 1A). The effect of mislocation of the ethynyl group by just
one bond length, using a butynyl instead of propargyl group in con-
struct SUMO2(DG)–Ba resulted in a dramatic decrease of the rate of
adduct formation (at least 480-fold; Fig. 1D; see also Fig. S3). The
importance of the catalytic cysteine of the protease for this reaction
was apparent from control reactions using enzymes that were
either genetically inactivated by a Cys-to-Ser mutation or chemi-
cally blocked by pre-treatment with the thiol-reactive NEM. In both
cases no adduct formation was observed (see Section 3.5 & Fig. 4A;
Fig. S4). In contrast, pre-incubation of the protease with progargyl-
amine in high excess (25,000-fold) did not block the reaction (dataFigure 2. Mechanism of covalent inhibition by an thiol–alkyne addition. (A) The known r
(R = peptide or protein); (B) proposed scheme of the reaction observed here leading to a
obtained by a tryptic digest using the His6–SUMO2(Q98R)(DG)–Senp1 adduct. The Q98
digestion; (D) ESI-MS analysis of the fragment shown in (C). Signals for the triple charg
Figure 3. Comparison in reactivity of the propargylated probe with the corresponding vin
in contrast to SUMO2(DG)–VS. (A) Schematic representation of SUMO2(DG) C-termin
SUMO2(DG)–VS; (C) were incubated with indicated concentrations of dithiothreitol (DTnot shown). Consistent with a participation of the active-site cys-
teine in covalent adduct formation, SUMO2(DG)–Pa acted as an
inhibitor of the protease Senp1 (Fig. S5).
3.2. Covalent adduct formation is also observed for ubiquitin
proteases with propargylated ubiquitin
A similar adduct formation could be observed between the
deubiquitinase USP5 and the corresponding Ub(DG)–Pa inhibitor,
however, within the evaluated reaction times no cross-reactivity
was detectable between the proteins taken from the SUMO and
Ub pathways (Fig. S6). These results underlined the high selectivity
and the generality of the reaction.eversible reaction of nitrile inhibitors with cysteine proteases to form a thioimidate
vinyl sulﬁde linkage; (C) structure of the fragment containing the covalent linkage
R mutation was introduced into SUMO2 to produce a smaller fragment by tryspin
ed ion: m/zcalc. = 848.3647, m/zobs. = 848.3650.
ylsulfone. SUMO(DG)–Pa does not undergo unspeciﬁc side-reactions with free thiols
ally modiﬁed with a glycine–vinylsulfone (VS) moiety. SUMO2(DG)–Pa; (B) and
T) for 1 h at room temperature prior to addition of Senp1.
Figure 4. Impact of Senp1 active site mutations on adduct formation with
SUMO2(DG)–Pa. (A) Protein components were incubated for 1 h at room temper-
ature before reactions were monitored via Coomassie-stained SDS–PAGE; (B) time-
dependent analysis of the reactions of SUMO2(DG)–Pa with wild-type (WT) Senp1
and Senp1H533A, respectively. See Figures S11 & S12 for further analyses of the
mutants.
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analyses reveal formation of a vinyl sulﬁde linkage
Thiols are known to undergo the thiol-yne reaction with al-
kynes, which follows a radical mechanism.33,34 However, the strict
exclusion of light and the presence of sodium ascorbate as a radical
scavenger35 in control experiments did not impair the formation of
the covalent adduct (data not shown), suggesting that this mecha-
nism did not apply here. On the other hand, unactivated alkynes
are known to undergo addition reactions with thiols in the pres-
ence of base to form the thiolate for nucleophilic attack.36 In the
case of activated alkynes with a neighboring electron-withdrawing
group, the reaction can proceed at slightly basic pH with
anti-Markovnikov regioselectivity and gives rise to the b-substi-
tuted vinyl sulﬁdes.37 The nucleophilic role of the active-site thiol
side chain in cysteine proteases, which is activated by a catalytic
triad (Cys–His–Asp) or at least a catalytic diad (Cys–His),11,12
would suggest that the present reaction follows this mechanism.
However, the a-substituted vinyl sulﬁde representing the Mark-
ovnikov product would be expected because the present alkyne
moiety lacked an electron withdrawing group in the propargylated
SUMO and Ub proteins and because of our observations on the
importance of the positioning of the quaternary carbon atom of
the alkyne group in the active site. In further support of this
hypothesis, we also noticed that the chemical structure of the
Ubl–Pa inhibitors and the dependence on the positioning of the al-
kyne moiety are reminiscent of the isosteric nitrile inhibitors.
These well-studied, covalent and reversible cysteine protease
inhibitors form a thioimidate38,39 with the active-site thiolate
(Fig. 2A). Taking all these considerations into account, we hypoth-
esized that the attack of the active-site cysteine onto the terminal
alkyne is a thiol–alkyne addition and results in the vinyl sulﬁde
shown in Figure 2B. Indeed, this model was supported by massspectrometric analysis of the covalent SUMO–Senp1 and Ub–
USP5 adducts. Following the tryptic digestion of the samples, the
fragments containing the new linkage could be detected and were
in agreement with the calculated masses (Fig. 2C–D & Fig. S7). The
identity of one fragment was further conﬁrmed by partial peptide
sequencing using MS/MS (Fig. S8). The proposed vinyl sulﬁde
structure has also been assigned by crystal structure analysis in
an independent study.25
We could ﬁnd one report in the literature on an alkyne inhibitor
tested on papain and papain-like proteases. A short dipeptide ana-
log with an N-terminal tert-Butyloxycarbonyl group showed
detectable inhibition of papain, yet 2000-fold weaker than the
isosteric nitrile counterpart, and was obviously not investigated
any further.40 We hypothesize that the lacking dipole moment of
the alkyne group compared to the nitrile and other electrophilic
groups has an impact on the binding and resident time of the
inhibitor in the active site. This effect should be particularly pro-
nounced for short peptide inhibitors with low binding afﬁnity,
but would not play a signiﬁcant role for SUMO and Ub proteases.
3.4. The propargyl moiety is less reactive than commonly used
electrophilic groups for protease inhibition
Surprisingly, despite the many known covalent inhibitors for
cysteine proteases and their systematic variations,11,12 an alkyne
group had not been successfully reported for this purpose,25 nei-
ther for Ub and Ubl proteases nor for cysteine proteases in general.
Obviously, chemical intuition suggested that this moiety is too
unreactive as an electrophile. The functional groups previously
used13–18 are typical electrophiles with graded reactivity that were
selected on their ability to preferably react with an active-site cys-
teine and to show only little background reaction with other thiols
and nucleophiles present in cellular mixtures in the relevant con-
centration range. To compare the reactivity of the new alkyne
probes with a typical representative of this group we chose the
vinylsulfone inhibitor SUMO2(DG)–VS (see Fig. 3A). Both probes,
SUMO2(DG)–Pa and SUMO2(DG)–VS, labeled Senp1 with a similar
rate during the investigated time period, with virtually complete
reactions 30 sec after mixing the reactants (Fig. S9A). However, dif-
ferences in reactivity became apparent when the probes were
incubated with puriﬁed Ubc9 protein. This SUMO-speciﬁc E2-con-
jugating enzyme also employs a catalytic, yet less reactive, cysteine
residue. While SUMO2(DG)–Pa failed to add to Ubc9 under the
conditions tested, the reaction with SUMO2(DG)–VS showed a par-
tial covalent adduct formation (Fig. S10). To further delineate the
higher inherent disposition of the vinylsulfone probe to react with
unrelated thiols, we performed a competitive quenching experi-
ment, in which increasing amounts of dithiothreitol (DTT) were
preincubated with SUMO2(DG)–Pa and SUMO2(DG)–VS before
the Senp1 protease was added (Fig. 3B and C). Indeed, whereas SU-
MO2(DG)–VS was partially quenched already at 1–10 mM DTT and
virtually completely inactivated at 50 mM DTT, no effect could be
observed in case of SUMO2(DG)–Pa for DTT at concentrations up to
1000 mM DTT (corresponding to an 100,000-fold excess over the
propargyl probe).
3.5. The key catalytic residues of Senp1 for thiolate formation
are not required for the thiol-alkyne addition
We next tested to what extent the key catalytic residues of
Senp1 were participating in the thiol–alkyne addition. As already
mentioned, the C603S mutation of the catalytic cysteine abrogated
covalent adduct formation and the same result was conﬁrmed for
the SUMO2(DG)–VS probe (Fig. 4A & Fig. S9B), as expected. To
our surprise, however, mutation of the other members of the
catalytic triad, H533A and D550A,41 had no detectable impact on
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ular the catalytic histidine is essential for converting the active-site
cysteine side chain into the reactive thiolate. Accordingly, the
H533A mutant was found to be inactive in proteolytic cleavage
of a SUMOylated model protein (Fig. S11) in agreement with previ-
ous reports.41 The inherent electrophilic nature of the vinylsulfone
could explain the efﬁcient Michael-addition even in the absence of
the protease-mediated thiol deprotonation,42 but the efﬁcient
reaction with the unactivated alkyne was unexpected. A time-
course analysis of this reaction revealed that virtually quantitative
adduct formation occurred already after 30 s, the ﬁrst time-point
taken, similar to the wild-type enzyme (Fig. 4B). The same results
were obtained when the pH of the reaction mixture was lowered to
pH 7 and pH 6 (Fig. S12A and B). Finally, we tested the importance
of glutamine 597, which is proposed to participate in the formation
of an oxyanion hole to stabilize the tetrahedral intermediate.41,43
Also the Q597A mutant rapidly formed the covalent adduct with
SUMO2(DG)–Pa (Fig. 4A & Fig. S12C). Together, these results sug-
gested that these key catalytic residues of Senp1 do not provide
an important contribution to the thiol-alkyne addition. When con-
sidering our observations on the strict dependence on the location
of the alkyne group we conclude that the precise positioning of the
two functional groups in the active site of the protease is necessary
and sufﬁcient. We therefore propose that this reaction is best de-
scribed as an in situ thiol-alkyne addition, following the use of this
term for other reactions that are driven by protein-mediatedFigure 5. Speciﬁc labeling of SUMO and ubiquitin proteases in cell lysates. Mouse N2a cel
Following cell lysis, propargylated SUMO and Ub probes were added, reaction mixture
analysis by western blotting. (A) The indicated probes were applied at of concentration of
prior to addition of 0.5 lM HA–SUMO2(DG)–Pa; (C) the probes were incubated with thproximity of the two reactants.44,45 We cannot strictly rule out po-
tential catalytic effects from other amino acids in the active site.
3.6. Propargylated SUMO and ubiquitin can serve as speciﬁc
probes for activity-based labeling in cell lysates
The high reactivity of the alkyne inhibitors and the resistance
against high thiol concentrations suggested an excellent potential
as suicide probes for the activity-based identiﬁcation of active en-
zymes in complex mixtures, such as cell extracts. A mouse N2a cell
line was transfected with expression plasmids for the deubiquitin-
ase USP5 and the SUMO protease Senp2. Indeed, following addition
of an HA-tagged SUMO2(DG)–Pa probe and an streptavidin-bind-
ing peptide (SBP)-tagged Ub(DG)–Pa probe to the cell lysates,
selective labeling of the respective proteases could be demon-
strated by western blotting (Fig. 5). Addition of NEM prior to the
probe blocked the reaction (Fig. 5B). We could not detect any unde-
sired reactions with other cellular components. Thus, the probes
behaved as expected and these initial experiments further sup-
ported their usefulness for this kind of application.
4. Conclusions
We have discovered an unexpected reaction25 between cysteine
proteases of the SUMO and ubiquitin family and their propargylat-
ed substrate proteins. The formation of a vinyl sulﬁde linkagels were transiently transfected with plasmids expressing eGFP–Senp2 and HA–USP5.
s incubated at room temperature, quenched, and loaded on SDS–PAGE gels before
0.5 lM. (B) the cell lysate was pre-incubated with 10 mM N-ethylmaleimide (NEM)
e cell lysate for 90 min at the indicated concentrations.
S. Sommer et al. / Bioorg. Med. Chem. 21 (2013) 2511–2517 2517inhibited the proteases. A mutational analysis of the key catalytic
residues in the active-site of the protease suggests that the thiol–
alkyne addition occurs in situ and is driven by the close proximity
and alignment of the two functional groups. Because of the bioin-
ertness of the terminal alkyne group, this reaction is useful for cel-
lular labeling reactions and is likely a valuable alternative to
existing reactions that are based on stronger electrophiles. More
generally, the alkyne moiety might also prove to be a powerful
addition to the arsenal of medicinal chemistry building blocks for
the development of cysteine protease inhibitors with therapeutic
value.
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